drugset / Trial / NCT06471257

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

NCT06471257

Phase 3 Recruiting 790 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

An event-driven, Phase III study to evaluate the efficacy and safety of BDA MDI compared with AS MDI in reducing the risk of a severe asthma exacerbation in symptomatic Chinese adults with asthma.

Timeline

Start
2024-06-17
Primary completion
2026-10-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Salbutamol Unknown 180 ug Inhaled

Indications